261 related articles for article (PubMed ID: 33490611)
1. Sequential therapy from entecavir to tenofovir alafenamide
Itokawa N; Atsukawa M; Tsubota A; Takaguchi K; Nakamuta M; Hiraoka A; Kato K; Abe H; Mikami S; Shimada N; Chuma M; Akito N; Uojima H; Ogawa C; Asano T; Tani J; Morishita A; Senoh T; Yamashita N; Oikawa T; Matsumoto Y; Koeda M; Yoshida Y; Tanabe T; Okubo T; Arai T; Hayama K; Iwashita AN; Kondo C; Tada T; Toyoda H; Kumada T; Iwakiri K
JGH Open; 2021 Jan; 5(1):34-40. PubMed ID: 33490611
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Ogawa E; Nomura H; Nakamuta M; Furusyo N; Koyanagi T; Dohmen K; Ooho A; Satoh T; Kawano A; Kajiwara E; Takahashi K; Azuma K; Kato M; Shimoda S; Hayashi J;
Liver Int; 2020 Jul; 40(7):1578-1589. PubMed ID: 32304611
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir.
Yuan GC; Chen AZ; Wang WX; Yi XL; Tu L; Peng F; Qiu ZH
World J Clin Cases; 2023 Dec; 11(34):8139-8146. PubMed ID: 38130795
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia].
Liu LP; Wu XP; Cai TP; Wang L; Sun J; Liang JY; Ma SP; Gan X; Ruan NH; Ge SF
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):118-125. PubMed ID: 37137825
[No Abstract] [Full Text] [Related]
5. Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
Kumada T; Toyoda H; Yasuda S; Ito T; Tanaka J
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e898-e904. PubMed ID: 35048656
[TBL] [Abstract][Full Text] [Related]
6. Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
Uchida Y; Nakao M; Yamada S; Tsuji S; Uemura H; Kouyama JI; Naiki K; Sugawara K; Nakayama N; Imai Y; Tomiya T; Mochida S
PLoS One; 2022; 17(2):e0262764. PubMed ID: 35180213
[TBL] [Abstract][Full Text] [Related]
7. Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
Uchida Y; Nakao M; Tsuji S; Uemura H; Kouyama JI; Naiki K; Motoya D; Sugawara K; Nakayama N; Imai Y; Tomiya T; Mochida S
J Med Virol; 2020 Mar; 92(3):329-338. PubMed ID: 31777965
[TBL] [Abstract][Full Text] [Related]
8. Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study.
Sato K; Inoue J; Akahane T; Kobayashi T; Sato S; Kisara N; Ninomiya M; Iwata T; Sano A; Tsuruoka M; Onuki M; Masamune A
Medicine (Baltimore); 2022 Sep; 101(39):e30630. PubMed ID: 36181074
[TBL] [Abstract][Full Text] [Related]
9. Comparison of tenofovir alafenamide and entecavir for hepatitis B virus
Peng W; Gu H; Jiang C; Liu J; Zhang J; Fu L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):194-201. PubMed ID: 35545409
[TBL] [Abstract][Full Text] [Related]
10. Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.
Hagiwara S; Nishida N; Ida H; Ueshima K; Minami Y; Takita M; Komeda Y; Kudo M
J Med Virol; 2019 Oct; 91(10):1804-1810. PubMed ID: 31199513
[TBL] [Abstract][Full Text] [Related]
11. Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long-term effects from a prospective study.
Hagiwara S; Nishida N; Ueshima K; Yoshida A; Minami Y; Kudo M
Hepatol Res; 2021 Jul; 51(7):767-774. PubMed ID: 33900663
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir.
Tamaki N; Kurosaki M; Kirino S; Yamashita K; Osawa L; Sekiguchi S; Hayakawa Y; Wang W; Okada M; Higuchi M; Takaura K; Maeyashiki C; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Enomoto N; Izumi N
JGH Open; 2020 Jun; 4(3):429-432. PubMed ID: 32514449
[TBL] [Abstract][Full Text] [Related]
13. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
Hepatol Int; 2022 Apr; 16(2):282-293. PubMed ID: 35075593
[TBL] [Abstract][Full Text] [Related]
14. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
Li ZB; Li L; Niu XX; Chen SH; Fu YM; Wang CY; Liu Y; Shao Q; Chen G; Ji D
Liver Int; 2021 Jun; 41(6):1254-1264. PubMed ID: 33404182
[TBL] [Abstract][Full Text] [Related]
15. Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B.
Ishido S; Tamaki N; Uchihara N; Suzuki K; Tanaka Y; Miyamoto H; Yamada M; Matsumoto H; Nobusawa T; Keitoku T; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Takahashi Y; Tsuchiya K; Nakanishi H; Itakura J; Kurosaki M; Izumi N
JGH Open; 2023 Aug; 7(8):567-571. PubMed ID: 37649865
[TBL] [Abstract][Full Text] [Related]
16. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
Aliment Pharmacol Ther; 2022 Aug; 56(4):713-722. PubMed ID: 35735794
[TBL] [Abstract][Full Text] [Related]
17. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial.
Iida-Ueno A; Enomoto M; Kozuka R; Tamori A; Kawada N
J Med Virol; 2019 Jul; 91(7):1295-1300. PubMed ID: 30815880
[TBL] [Abstract][Full Text] [Related]
18. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.
Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
Hepatol Int; 2021 Oct; 15(5):1083-1092. PubMed ID: 34402025
[TBL] [Abstract][Full Text] [Related]
19. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
Li J; Hu C; Chen Y; Zhang R; Fu S; Zhou M; Gao Z; Fu M; Yan T; Yang Y; Li J; Liu J; Chen T; Zhao Y; He Y
BMC Infect Dis; 2021 Jun; 21(1):567. PubMed ID: 34126939
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy.
Lee IC; Lan KH; Su CW; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
